{"name":"Janssen-Cilag, S.A.","slug":"janssen-cilag-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Rabeprazol","genericName":"Rabeprazol","slug":"rabeprazol","indication":"Duodenal Ulcer due to H. Pylori","status":"discontinued"},{"name":"Vagitrol V","genericName":"Vagitrol V","slug":"vagitrol-v","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"antipsychotic medications","genericName":"antipsychotic medications","slug":"antipsychotic-medications","indication":"Other","status":"phase_2"},{"name":"antipsychotics","genericName":"antipsychotics","slug":"antipsychotics","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fentanyl-TTS","genericName":"Fentanyl-TTS","slug":"fentanyl-tts","indication":"Chronic pain in opioid-tolerant patients","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Gynoclin V","genericName":"Gynoclin V","slug":"gynoclin-v","indication":"Bacterial vaginosis","status":"phase_3"}]}],"pipeline":[{"name":"Fentanyl-TTS","genericName":"Fentanyl-TTS","slug":"fentanyl-tts","phase":"marketed","mechanism":"Fentanyl-TTS is a transdermal patch that delivers the opioid fentanyl through the skin at a controlled rate to provide long-acting pain relief.","indications":["Chronic pain in opioid-tolerant patients","Cancer pain","Severe chronic pain requiring opioid therapy"],"catalyst":""},{"name":"Rabeprazol","genericName":"Rabeprazol","slug":"rabeprazol","phase":"discontinued","mechanism":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","indications":["Duodenal Ulcer due to H. Pylori","Duodenal ulcer disease","Gastroesophageal reflux disease","Maintenance of Healing Gastroesophageal Reflux","Multiple endocrine adenomas"],"catalyst":""},{"name":"Gynoclin V","genericName":"Gynoclin V","slug":"gynoclin-v","phase":"phase_3","mechanism":"Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections.","indications":["Bacterial vaginosis","Vaginal infections caused by susceptible bacteria"],"catalyst":""},{"name":"Vagitrol V","genericName":"Vagitrol V","slug":"vagitrol-v","phase":"phase_3","mechanism":"Vagitrol V is a medication that works by inhibiting the action of a specific enzyme.","indications":["Gastroesophageal reflux disease (GERD)","Erosive esophagitis"],"catalyst":""},{"name":"antipsychotic medications","genericName":"antipsychotic medications","slug":"antipsychotic-medications","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antipsychotics","genericName":"antipsychotics","slug":"antipsychotics","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNZHRwMDBhZTNvcW9kNnZKNHVFX2dXckkxTnk0aGZER0dVWkNCTEZyNVFESnNtZ08zdkRydkV6OTYyOU9fMWVZNFl3VEE1SHQwR25ZcXhkc1RtZnphZF8tZFVPSUJ2T2hMelRqUGN3bFZoOW9hOEthWXhLSkhwLUhlOGVnUk9mN3Q2TV8yQVYxUkt4QWFBb1h2cHhNQy1IOWluWG9vY0NseVNuWFowNG5jYlZQLUNlWFFJeHlJUE1idy1sVm9OcXRINGxKeTd2dEttRHN1cU5VODJ1cDNXanJEcFN3?oc=5","date":"2026-02-17","type":"trial","source":"TipRanks","summary":"AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027 - TipRanks","headline":"AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9sVEdZeFJYblU4anJlUEU5ZnJscTB2N2lYazZDODZPM2djNVNFdWt6TnNFSXpMa3pocFpOam9uNThsVkNXNmhJOFc5ejZ5ZVdJT0ozWVdPLWx3NnRkaklZR0QxUEZtUGp6dmhwWFpsRXRTdw?oc=5","date":"2025-12-15","type":"regulatory","source":"Straits Research","summary":"Ankylosing Spondylitis Market Size, Top Share, Demand | Industry Report, 2034 - Straits Research","headline":"Ankylosing Spondylitis Market Size, Top Share, Demand | Industry Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPRWxYOVBsbHRyRGVhaF8yMFZCOXNjN2NaTS1KSnhudnd4SFlyVUM5ZWlIUU5iWkgyXzFXVlR1eTFCZ2NsTU1uWG5za3JyRlhsclcwdTdOY3FaQXdSOTVUOEVEWmlOWnBtcFVSY1VfQURTcVAtZ2tPQ1g3a0ZUeXllNl82ZDJJZDQyZEo5QzFjT3cyTkRVZmtrM29n?oc=5","date":"2025-12-03","type":"pipeline","source":"ASCO Daily News","summary":"Personalizing Treatment of BRAF -Mutant Gastrointestinal Tumors - ASCO Daily News","headline":"Personalizing Treatment of BRAF -Mutant Gastrointestinal Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNSHJIVW1uenJRUHN1TjI1MGJjUUFQYUdIQm9MRUFUNENMYVdwRVlvUnFTTTNqZ0RXTXdoc2RyU242TmlSbjhKZHJHQWhKU09ERC11TWtoREl2SDVVZTBkWVdxNWdNY005d3J1V1N5NFNDNVprX0hjaHFhUmVtb0VIY1RLUUc3THYxWUZxcmtld0JINl92TTUw?oc=5","date":"2025-10-20","type":"pipeline","source":"Frontiers","summary":"Digital technologies in psoriasis management: from precision diagnosis to therapeutic innovation and holistic care - Frontiers","headline":"Digital technologies in psoriasis management: from precision diagnosis to therapeutic innovation and holistic care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxORERIUUtfcFhfNnEyMW9nb3djSjdiQ1VWR0pUbWN2YXdCaFFzMTR4cGZBbE1LbVA0ODFoYVBxR013MjVwN1pOb1k1aldkY3VMdUlHbTZnQWVxYmJUZTQxenpHVGc1QnlJODdFcmVQZHl2Skk2T0ZIaGt0a3haSERLYzI4V1FqMnBKbWFaS2NGTTZCSUxUdVFTNWxPSndkWkk?oc=5","date":"2025-09-30","type":"pipeline","source":"lupin.com","summary":"Lupin Launches Rivaroxaban for Oral Suspension in the United States - lupin.com","headline":"Lupin Launches Rivaroxaban for Oral Suspension in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQUzgtM0JLX1NPVmZWYUdCOXA1a1F6d28yR3dUZVRNNmhGYjJaTGZMLTFORVpWaG5aOWtQNzFSYi12cVlNSGR2TUg1TVBXbzhscmxmU2lDaS1Qc2s5MlJMcEY4N3BYM1pwYS1mZUt1cjR1SFZtREY0NzdVaXJzUDRqYTFxUVQ5anJyaGNNUUVDd0xsZm1YeGc5YkFkNHZNNS1jME04bVNtSFl3bDJkQ0FVRkVxQ2VVY3lub3E3Y1BsVzZZSDNUVWNBdTNtOWd5UFFCLS0zckdTaXFLUjJKaG1LblliWHk2SXBXM0xqN09JeXVMVWZ6emZxSHdQSEIxTjc1TFNqOHlnNlhPZTJGckE?oc=5","date":"2025-08-04","type":"pipeline","source":"ICLG.com","summary":"Pharmaceutical Advertising Laws and Regulations Report 2025-2026 When Criticising Competitor Products Becomes an Antitrust Problem: Disparagement in Competition Law - ICLG.com","headline":"Pharmaceutical Advertising Laws and Regulations Report 2025-2026 When Criticising Competitor Products Becomes an Antitru","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQUVNQYnlMZFZDQ0xXZU1NRnNqaElIeUpKMC1raV9DSzNVRjF4Mzlyb1IwY0xRNE4xTHd6empEaUhPcjc0RHNPZ3dmZHY1cThhTm1JRVRpRi03QWlVY1d0Ry1FSEdoSXlMdHlBeVU2U2ltQmJwVm4yMUFqcUctRUNBNTJTUHgxS1RpVGlEa28xaFpQZXE4aE9uWmYxSmQzc1M5UVFiVXVwZ3NXS01FbVlyMGU5QXlkbFBoQnpEVk1vZF9rbXFxUEVZUDJGaW5uYkZUNkdUOS1FN2t6Yzh2RVdZdElTZjJmZ3pCMXZvdmlnclVDMEIxU0d1ODdibGJTcG5uQnNLLTRR?oc=5","date":"2025-07-17","type":"regulatory","source":"Johnson & Johnson","summary":"Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer - Johnson & Johnson","headline":"Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer - Jo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBGRUhfZDc2VTFFQUo3WUpaaTFGRjR4cmVDTjBuRkNHUTFZbEg1Y0tZSVZfSDFLLUhzNElXTzg4WjBzRmVOTWNyWlVzeUU1blZzMmVKYno2bHdXVTdBNWpQNA?oc=5","date":"2025-01-20","type":"pipeline","source":"Market.us","summary":"Rivaroxaban Market Size, Share | CAGR Of 6.8% - Market.us","headline":"Rivaroxaban Market Size, Share | CAGR Of 6.8%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSnR6RnU2THRzUUluS01zdUptVFFLRm1wTDloRk9tamtEamRGU1k0ZU1Vem5YVTBmRVYtaktxRW84emF1OExFZHV5Vm1Fajk4WVdqcklBamtFX2c1eGZ0V0gzOHNGdUJpRFNYYjBYcVJzbFdRdDZGRHVPYjhYdTMyOGExN1BLNm44?oc=5","date":"2024-07-22","type":"pipeline","source":"Contract Pharma","summary":"Big Pharma Ramps up Expansion to Emerging Markets - Contract Pharma","headline":"Big Pharma Ramps up Expansion to Emerging Markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdDZndFlHVk91cHRuSk9qcVk2YVlkQlFFSGJRb3pxTzJlV1d2LWFOak9TRllscks3Z2JQcThacW4tamlCS1g1ZlJzczlETHQzUm5RR1NIRmJfMHVTcmhNZms5bXFlWDY2V3ItbmwxX1ludzFsb1VYX2dkbEdaOTZaamdCcHR1MjRpRmZzMDdCUDM1Umc0UEJiS2g4NWI?oc=5","date":"2023-10-03","type":"pipeline","source":"European Biotechnology Magazine","summary":"Sanofi licences vaccine against bacterial sepsis - European Biotechnology Magazine","headline":"Sanofi licences vaccine against bacterial sepsis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQQzlIc2EzYXBLZFdBY0lZZ3pJWGhhWFFxSFh5OXoyNVV0OHZWTlRhMklMSUxXR0JNU0huTnI1MUZsX2tSV25GY2tTb3BVV1gweTE4cnY5OUdlczhvMFRRSWhtRnBaOFh0NnhWcWFXV3pOQ29VWVdwd1BrTzNqVDNzdVZYVzVfa2xnNnVrQjFxSVkyM0VvZGNmS2drc1NQejUtbUk2S2hfSnBfWHFvVy1GZGFPank1eHJTZGRXQWhDaFJ1SC1UNkNqT2R3blNOb2U1dDA0NnpZaF9pODZPaEVQN2c2aENIYlFBM21pMQ?oc=5","date":"2020-09-29","type":"deal","source":"prnewswire.com","summary":"M8 Pharmaceuticals announces strategic partnership with Janssen for selected CNS Portfolio in Mexico - prnewswire.com","headline":"M8 Pharmaceuticals announces strategic partnership with Janssen for selected CNS Portfolio in Mexico","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":2,"discontinued":1,"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}